News
Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S.
Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.
Hyderabad: Amid rising fears of US President Donald Trump imposing tariffs on Indian pharma imports, Aurobindo Pharma is ...
Aurobindo Pharma to acquire US-based Lannett for $250M, gaining a strategic local manufacturing base to offset tariffs and ...
Hyderabad: In a major strategic move, Aurobindo Pharma Limited has announced that its wholly owned subsidiary, Aurobindo ...
The deal is being carried out on a cash-free, debt-free basis, factoring in standardised working capital levels.
The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including ...
Aurobindo Pharma USA acquires Lannett Company LLC for $250 million, expanding U.S. manufacturing capabilities and product ...
TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has been completed in the pivotal clinical trial of biosimilar insulin glargine, a ...
Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results